Syngene Names Former Biocon CEO Siddharth Mittal as Managing Director and CEO

Syngene, a global contract research, development and manufacturing organisation (CRDMO), said Mittal brings nearly three decades of business leadership experience and joins the company from Biocon Limited, where he most recently served as Managing Director and Chief Executive Officer.

During his 13-year tenure at Biocon, Mittal held the role of Chief Financial Officer before being elevated to MD & CEO. The company said he played a key role in shaping Biocon's long-term growth strategy, strengthening its commercial operations, expanding its global footprint, securing regulatory approvals and commercialising the company's GLP-1 portfolio across major international markets. He also led strategic partnerships and commercial initiatives aimed at improving operational excellence, customer-centricity and sustainable business growth.

Commenting on the appointment, Kiran Mazumdar-Shaw, Executive Chairperson of Syngene International, said, "I am delighted to welcome Siddharth as the Managing Director and CEO of Syngene. Having worked closely with Siddharth for many years, I have seen firsthand his ability to lead businesses through periods of change, build strong teams and deliver transformation and sustainable growth. Having built a strong reputation for scientific excellence, quality and customer trust, Syngene is now at an inflection point in its journey. As the industry evolves and customer expectations continue to rise, I am confident Siddharth's leadership, commercial acumen and execution focus will help Syngene unlock its full potential and create long-term value for our customers, employees and shareholders."

Expressing his views on assuming the role, Siddharth Mittal said, "I am honoured to take on the role of Managing Director and CEO of Syngene. Over the years, the company has built exceptional scientific capabilities, a talented team and gained the trust of customers across the world. These enduring strengths give us a solid platform to drive the next phase of long-term growth. My immediate priority is to sharpen our commercial edge, strengthen delivery excellence and bring greater focus and discipline to execution across the business. By combining our scientific strengths and talented workforce with an unwavering focus on customer fulfilment and cost competitiveness, I am confident that we can restore growth momentum and reinforce Syngene's standing as a global leader in CRDMO services, while creating long-term value for all our stakeholders."

Also Read: Syngene International, Bristol Myers Squibb Extend Strategic Collaboration Through 2035

Syngene International is an integrated research, development and manufacturing services company serving the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemicals sectors. The company has more than 8,300 employees, including over 5,700 scientists, and operates over 3 million sq. ft. of research and manufacturing infrastructure across India and the United States. It serves approximately 400 global customers, including leading multinational companies such as Bristol Myers Squibb (BMS), GSK, Zoetis and Merck KGaA.